Acetamidobenzoxazolone conjugated DOTA system for assessing 18 kDa translocator protein during pulmonary inflammation

Abstract

Translocator protein (TSPO) is well known inflammatory target. We have designed a new molecule DOTA-MBP. In-silico studies have been performed to evaluate the binding affinity potential of MBP towards the TSPO. The stability of DOTA-MBP was assessed for Gd (III) for possible application as chelating vehicle or other MR contrast agent. For in vivo studies LPS induced lung inflammation model was develop in mice and after 24 h of LPS administration biodistribution and 99mTc-DOTA-MBP imaging have been performed to monitor the uptake and distribution of radioactivity in different peripheral organs with time. In conclusion we can say that DOTA-MBP as potential candidate to locate the lung inflammation as well as monitor the severity of disease through SPECT or MRI.